Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31535959 | 0.85 | HTR2A (0.39) | TRPV4SLC22A12 | |
| SCHEMBL31137082 | 0.81 | DPP4 (0.36) | SCN9ASCN5A | |
| SCHEMBL18215048 | 0.78 | TRPV4 (0.46) | TRPV4 | |
| SCHEMBL3157145 | 0.77 | TRPV4 (0.45) | TRPV4 | |
| SCHEMBL17610841 | 0.77 | RORC (0.41) | TRPV4SLC22A12EPAS1 | |
| SCHEMBL22817321 | 0.77 | SCN9A (0.33) | SCN9ASCN5A | |
| SCHEMBL13766377 | 0.76 | TRPV4 (0.50) | TRPV4 | |
| SCHEMBL857212 | 0.76 | SCN5A (0.32) | SCN9ASCN5A | |
| SCHEMBL28724728 | 0.75 | TRPV4 (0.40) | TRPV4SLC22A12 | |
| SCHEMBL17610774 | 0.71 | TRPV4 (0.40) | TRPV4AOC3EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4299135-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3986890-B9 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4299135-A2 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | Pfizer Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3986890-B1 | BENZISOXAZOLE SULFONAMIDE DERIVATIVES | PFIZER (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | MONASH UNIVERSITY (AU) | 2023-06-08 | — | — | US | disclosed |
| US-20080090800-A1 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2008-04-17 | — | — | US | disclosed |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-09-20 | — | — | US | disclosed |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-08-30 | — | — | US | disclosed |
| US-7129233-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20060052314-A1 | Pharmaceutical combination | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090800-A1 | Mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | TRPV4 4020/4885AOC3 1987/4885SLC22A12 3536/4885 |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | TRPV4 3575/4885AOC3 3528/4885SLC22A12 2606/4885 |
| US-12371425-B2 | Benzisoxazole sulfonamide derivatives | BRIX1, RB1, BCR | TRPV4 2910/4885AOC3 4397/4885SLC22A12 2479/4885 |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | TRPV4 4080/4885AOC3 2080/4885SLC22A12 3489/4885 |
| US-20060052314-A1 | Pharmaceutical combination | F2, TNNT2, WFS1 | TRPV4 723/4885AOC3 3691/4885SLC22A12 3986/4885 |
| US-20260062406-A1 | Benzisoxazole Sulfonamide Derivatives | KAT8, KAT5, KAT7 | TRPV4 3638/4885AOC3 4192/4885SLC22A12 1668/4885 |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | TRPV4 4080/4885AOC3 2080/4885SLC22A12 3489/4885 |
| US-20230174522-A1 | Benzisoxazole Sulfonamide Derivatives | BRIX1, RB1, BCR | TRPV4 2910/4885AOC3 4397/4885SLC22A12 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.